Crossmark Global Holdings Inc. Decreases Stock Holdings in Becton Dickinson and Co (NYSE:BDX)

Crossmark Global Holdings Inc. trimmed its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 4.6% in the 4th quarter, Holdings Channel reports. The firm owned 13,793 shares of the medical instruments supplier’s stock after selling 666 shares during the period. Crossmark Global Holdings Inc.’s holdings in Becton Dickinson and were worth $3,751,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp raised its holdings in shares of Becton Dickinson and by 1.7% during the fourth quarter. State Street Corp now owns 11,450,583 shares of the medical instruments supplier’s stock valued at $3,114,215,000 after purchasing an additional 186,285 shares during the last quarter. Fiera Capital Corp raised its holdings in shares of Becton Dickinson and by 6.0% during the fourth quarter. Fiera Capital Corp now owns 3,454,596 shares of the medical instruments supplier’s stock valued at $939,547,000 after purchasing an additional 194,629 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Becton Dickinson and by 33.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,152,328 shares of the medical instruments supplier’s stock valued at $544,452,000 after purchasing an additional 543,512 shares during the last quarter. Comgest Global Investors S.A.S. raised its holdings in shares of Becton Dickinson and by 4.5% during the third quarter. Comgest Global Investors S.A.S. now owns 1,090,450 shares of the medical instruments supplier’s stock valued at $275,840,000 after purchasing an additional 46,600 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Becton Dickinson and by 1.8% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,051,417 shares of the medical instruments supplier’s stock valued at $285,954,000 after purchasing an additional 18,537 shares during the last quarter. 84.67% of the stock is owned by hedge funds and other institutional investors.

Shares of BDX stock opened at $260.22 on Friday. Becton Dickinson and Co has a 12 month low of $221.47 and a 12 month high of $286.72. The stock has a market cap of $68.97 billion, a P/E ratio of 95.67, a P/E/G ratio of 2.00 and a beta of 1.08. The company has a current ratio of 0.96, a quick ratio of 0.55 and a debt-to-equity ratio of 0.80. The company has a 50 day simple moving average of $271.90 and a two-hundred day simple moving average of $258.71.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, February 6th. The medical instruments supplier reported $2.65 EPS for the quarter, beating the Zacks’ consensus estimate of $2.63 by $0.02. Becton Dickinson and had a net margin of 4.96% and a return on equity of 15.50%. The business had revenue of $4.23 billion during the quarter, compared to analysts’ expectations of $4.19 billion. During the same period in the prior year, the company earned $2.70 earnings per share. The firm’s revenue was up 1.6% on a year-over-year basis. As a group, equities analysts forecast that Becton Dickinson and Co will post 11.97 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be paid a $0.79 dividend. The ex-dividend date is Monday, March 9th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 1.21%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.05%.

Several research analysts have recently weighed in on the stock. Cowen cut shares of Becton Dickinson and from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $306.00 to $275.00 in a report on Thursday, February 6th. KeyCorp boosted their price objective on shares of Becton Dickinson and from $284.00 to $298.00 and gave the company an “overweight” rating in a report on Wednesday, January 22nd. Piper Sandler upped their target price on shares of Becton Dickinson and from to and gave the company an “overweight” rating in a report on Thursday, February 6th. Morgan Stanley reduced their target price on shares of Becton Dickinson and from $287.00 to $271.00 and set an “equal weight” rating for the company in a report on Friday, February 7th. Finally, JPMorgan Chase & Co. upped their target price on shares of Becton Dickinson and from $285.00 to $300.00 and gave the company an “overweight” rating in a report on Friday, December 20th. Eight research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Becton Dickinson and currently has an average rating of “Hold” and an average price target of $279.38.

In other news, EVP Patrick Kaltenbach sold 339 shares of the stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $263.23, for a total value of $89,234.97. Following the completion of the sale, the executive vice president now directly owns 19,546 shares of the company’s stock, valued at $5,145,093.58. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Vincent A. Forlenza sold 11,626 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $265.57, for a total transaction of $3,087,516.82. Following the completion of the sale, the chief executive officer now directly owns 225,393 shares of the company’s stock, valued at $59,857,619.01. The disclosure for this sale can be found here. Over the last three months, insiders sold 133,539 shares of company stock valued at $36,646,395. Corporate insiders own 0.12% of the company’s stock.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: What is a Call Option?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.